Imara ROE 2024

Imara는 무엇을 하나요?

Imara Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for rare blood diseases. The company was founded in 2016 by experienced industry veterans who shared a vision of developing new and more effective treatments for patients with rare blood diseases. Imara is headquartered in Boston, Massachusetts, and has a subsidiary in Lausanne, Switzerland. Imara's business model is based on identifying unmet medical needs in the treatment of rare blood diseases and developing drugs that can address these needs. The company has focused on closing treatment gaps by developing new therapeutics that target the suppression of inflammatory isoforms of an enzyme called PDE9. These isoforms are often elevated in patients with rare blood diseases and contribute to disease worsening. Imara has several therapeutics in various stages of clinical development. The lead product, IMR-687, is an oral medication for the treatment of sickle cell anemia and β-thalassemia. IMR-687 has the potential to significantly reduce the frequency and severity of pain episodes in sickle cell patients while also lowering the risk of lung infections. Other potential areas of application for the medication include pulmonary hypertension, kidney diseases, and other blood disorders. Imara also has a pipeline of other compounds, including IMR-816 (another PDE9 inhibitor), which is currently in phase 1 studies for the treatment of amyloidosis. Amyloidosis is a rare protein deposition disorder that can affect various organs such as the heart, kidneys, liver, or nervous system. Furthermore, Imara is working on developing IMR-687 as a therapy for inherited blistering disorders. This rare condition, also known as "epidermolysis bullosa," is a genetically based skin disorder characterized by chronic wounds and scarring. It significantly impairs the quality of life for those affected. Imara collaborates closely with patient organizations, academic institutions, and regulatory authorities to ensure that its products can be made accessible quickly and safely. The company pursues a comprehensive clinical development strategy to reduce the impact of rare blood diseases on patients. Overall, Imara is a dynamic company focused on meeting medical needs and providing an excellent working environment for dedicated and goal-oriented employees. Imara hopes to continue its commitment to innovation and excellence as it continues to grow and focuses on improving the lives of people with rare blood diseases. Imara ist eines der beliebtesten Unternehmen auf Eulerpool.com.